Trial Profile
A Phase II Study of ABBV-399 in Patients With C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Telisotuzumab vedotin (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms LUNG-MAP SUB-STUDY
- 21 Sep 2021 Status changed from active, no longer recruiting to completed.
- 28 Jun 2021 Planned End Date changed from 1 Oct 2022 to 30 Jul 2021.
- 20 Jun 2019 Planned End Date changed from 5 Jan 2022 to 1 Oct 2022.